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Abstract
Aging is an important risk factor for patients with atrial fibrillation. The esti-
mated prevalence of atrial fibrillation in patients aged ≥80 years is 9–10%, with 
four- to fivefold increased risk of embolic stroke and with an estimated increased 
stroke risk of 1.45-fold per decade in aging. Older age is also associated with 
increased risk of major bleeding with oral anticoagulant (OAC) therapy. In this 
chapter, we will focus on the role of oral anticoagulation with new oral anticoagu-
lants, non-vitamin K antagonist, in populations with common comorbid condi-
tions, including age; chronic kidney disease; coronary artery disease, on multiple 
medication; and frailty. In patients 75 years and older, randomized trials have 
shown new oral anticoagulants to be as effective as warfarin, or in some cases supe-
rior, with an overall better safety profile, consistently reducing rates of intracranial 
hemorrhages. Prior to considering oral anticoagulant therapy in an elderly frail 
patient, a comprehensive assessment should be performed to include the risk and  
benefits, stroke risk, baseline kidney function, cognitive status, mobility and falling 
risk, multiple medication, nutritional status assessment, and life expectancy.
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1. Introduction
Atrial fibrillation (AF) is the most common arrhythmia in our daily clinical 
practice, affecting 4.5 million people in Europe and approximately 33.5 million 
people globally [1]. Estimates suggest a significant increase in AF incidence with 
age from 4.1/1000 under 75 years to 26.3/1000 in people older than 75 years [2]; in 
the same way, its prevalence rises from 0.1% in people under 55 years to 9% of those 
older than 80 [3–5], with an average annual cost of 2.365 € for each patient [6]. Due 
to the increase in life expectancy, the number of elderly people over 80 years with 
non-valvular AF (NVAF) will be fourfold in 2050; therefore, this group will repre-
sent over the 50% of the total of patients with this arrhythmia [4, 5], and stroke risk 
will increase 25–36% in elderly individuals between 80 and 89 years old [2, 7, 8].
Although people over 75 years present worse prognosis, higher mortality, and 
more adverse effects than those with age between 65 and 74 years [8], up to 35% 
of octogenarians do not receive oral anticoagulant (OAC) therapy [5]. The use of 
vitamin K antagonists (VKA) is reduced up to 14% for each decade of increase in 
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age, regardless of other stroke risk factors [5, 9]. Frequent reasons for not initiating 
antithrombotic treatment in frail older individuals are (1) antiplatelet therapy, (2) 
more than 90 years, (3) falling risk, and (4) nursing home residents, even though a 
strong indication and evidence show that frailty increases stroke risk but not major 
bleeding risk [10].
In Europe, since 2011, there is an available new family of OAC with indication 
for stroke and venous thromboembolism prevention in patients with NVAF. This 
new family includes four direct oral anticoagulants (DOACs), dabigatran (an active 
direct thrombin inhibitor), apixaban, edoxaban, and rivaroxaban (direct factor Xa 
inhibitors). Different meta-analyses have proved up to 20% reduced stroke risk, 
12% reduced mortality, and 50% reduced intracranial bleeding risk, in comparison 
with warfarin, showing fewer drugs and food interactions, with no control needed 
[9, 11]. The cost-utility of these drugs has been tested by cost-effectiveness analysis 
[6], and benefits shown are maintained regardless of age, presenting a greater 
reduction on all-cause mortality, stroke, and major, intracranial, and total bleedings 
in older individuals, the ones that present a higher risk [12–14].
Nonetheless, studies specifically designed in elderly population are not yet avail-
able, and the current evidence exclude multimorbidity patients, polypharmacy, and 
geriatric syndromes and just evaluate the benefit using health indicators with low 
clinical impact in this population [15–17]. In addition, the mean age of the patients 
included in clinical trials is 5–10 years lower than mean age of real-life patients with 
NVAF; because of that, the current guidelines are not able to make strong recom-
mendations for individuals of 85 years or more [5, 18]. In order to solve this lack 
of evidence, data from sub-group phase III pivotal trials have been used, including 
over 30,000 patients older than 75 years, to demonstrate efficacy of DOACs in 
comparison to VKA, showing equal safety profile in the older ones than in younger 
people [9, 19, 20] (Figure 1).
Anticoagulation in elderly patients supposes a huge challenge because of the 
frequent association with health conditions that can modify not only the therapy indi-
cation but also the type and dosage of drug, tolerance, adhesion, safety profile, and 
the results we seek. Among these health determinants, we highlight frailty, disability, 
comorbidity, polypharmacy, cognitive impairment, risk of falling, nursing home resi-
dents, nutritional status, oral feeding problems, sensory disorder, and personal and 
social issues [2, 21]. A complete comprehensive geriatric assessment (CGA) focused 
in identifying all these factors, combined with aging biology knowledge, a good 
Figure 1. 
Rates of very elderly subjects present in pivotal studies of DOAC.
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calculation of global and disability-free life expectancy, and a better knowledge of 
elderly pharmacology and individuality side effects of OAC in this population includ-
ing long time to benefit, will allow us to get a better adequacy of this therapy and to 
reach better health results. More clinical trials including frail aging patients and all 
these factors are needed in order to achieve real-life elderly population representative 
samples to better adjust OAC therapy in this group of age [18, 22].
2. Medication considerations in elderly patients
2.1 Thromboembolic and bleeding risk
The thrombotic risk in patients with NVAF is stratified by the CHA2DS2-VASc 
score: in patients with CHA2DS2-VASc score of 0, the thrombotic risk does not 
overweigh the risk of bleeding, so OAC is not recommended, but a CHA2DS2-VASc 
score of 1 or more reverses the risk/benefit balance, and anticoagulation is clearly 
recommended with class IA indication [23, 24].
The uncertainty arises when the score is 1; as in these patients, the stroke rate 
varies widely.
The thrombotic risk increase with higher CHA2DS2-VASc score. In elderly 
patients (75 years or older), OAC is always suitable; however, we may assess each 
case individually and evaluate bleeding risk, which is the most important complica-
tion in the anticoagulation treatment [24, 25].
Bleeding events are the most important complication of antithrombotic treat-
ment, so this requires us to personalize decision-making, especially in elderly 
patients with multimorbidity, geriatric syndromes, frailty, or disability.
There are several scores that help us to measure bleeding risk [26], which take 
into account different factors associated with increasing bleeding risk, with no 
intention of contraindicating OAC but to modify them with our intervention, in 
order to increase anticoagulation therapy’s security profile.
The most widespread one is HAS-BLED score, which includes different deter-
minants, all of them potentially modifiable, except the age. Other scores, like 
HEMORR2HAGES score, add some aspects that are usually included in CGA (falls, 
cognitive impairment) susceptible to evaluation and management by a geriatrician. 
The ATRIA bleeding risk score takes into account five parameters and stratify the 
bleeding risk into three levels [27, 28]. The ORBIT risk score proposes five determi-
nants: age, anemia, previous bleeding episodes, renal impairment, and antiplatelet 
therapy. This one demonstrates similar discrimination with better sizing than HAS-
BLED and ATRIA scores, according to ROCKET AF trial [29]. The ABC-bleeding 
score includes age, previous bleeding episodes, and three serum biomarkers (hemo-
globin, troponin T, and GDF15 or cystatin C/creatinine clearance) and obtains more 
appropriated results than HAS-BLED and the ORBIT, according to ARISTOTLE 
and RE-LY trials [27], but biomarkers are not standardized, and there is no defined 
cut point (class IIb indication).
2.2 Suitable control of anticoagulation
Antithrombotic treatment efficacy mostly depends on an adequate maintenance 
of anticoagulation levels, universally measured in VKA treatment by the “interna-
tional normalized ratio” or INR (therapeutic range from 2.0 to 3.0).
The poor control of anticoagulation according to INR represents one of the 
independent predictors most related with thrombotic and bleeding complications 
showing in several trials [30].
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Different methods have been proposed to define VKA anticoagulation quality 
like control percentage out of therapeutic range, control cross-sectional analysis, 
and time in therapeutic range (TRT), being the last one the most widely accepted 
and related with complication incidence (stroke, bleeding, and mortality) [30].
The INR is considered suboptimal when TRT calculated by Rosendaal method 
[31] (assumes a linear progression between two INR values and calculates the 
specific INR for each day) is fewer than 65%. Actually, labile INR is one of the items 
included in HAS-BLED score, and whereas an INR value above 70% is associated 
with an optimal efficacy and security level, lower values increase stroke risk, major 
bleeding, and mortality, associating even worse prognosis than patients with NVAF 
not receiving antithrombotic treatment.
2.3 Frailty and falls
Frail elderly patients with NVAF must be considerately able to receive antico-
agulation therapy, because of their increased vulnerability and higher functional 
worsening risk and disability. It is necessary to properly distinguish in the differ-
entiation between frailty (autonomous elderly with risk of functional impairment) 
and disability (functional impairment established with a greater or lesser degree of 
autonomy) of dependency (established disability). Frailty might precede by several 
years the development of disability and other clinical outcomes and is a major risk 
factor for non-catastrophic disability [32].
The comprehensive geriatric assessment (CGA) associated with performance 
status test, like short performance physical battery (SPPB) or gait speed measure-
ment, is the suitable tool to assess an individualized therapeutic decision [33–35]. 
Once we identify a frailty elderly, we must initiate multicomponent exercise inter-
vention that has demonstrated reduction of multimorbidity, disability, dependence, 
and, thus, institutionalization and death.
Oral anticoagulation has been proposed to increase intracranial bleeding risk 
due to traumatic brain injury related with falls, and this has been used as a contra-
indication to initiate anticoagulation, increasing its under prescription as the result 
[36]. The evidence is limited because patients with falls are excluded from trials and 
also there are papers that deny that patients with OAC and higher risk of falls have 
increased risk of severe bleedings [37].
However, the benefit in patients with high risk (CHA2DS2-VASc >3) exceeds the 
risk of falls [38]. It has been estimated that a patient with anticoagulation treatment 
has to fall 295 times in a year so that the risk exceeds benefit of treatment [39]. 
Between DOACs, only edoxaban was assessed in patients with atrial fibrillation 
judged to be at increased risk of falling. No treatment interaction was observed 
between either dosing regimens of edoxaban and warfarin for the efficacy and 
safety outcomes. Treatment with edoxaban resulted in a greater absolute risk reduc-
tion in severe bleeding events and all-cause mortality compared with warfarin [40].
2.4 Polypharmacy
Polypharmacy is defined as the chronic administration of five or more drugs, 
and this may determine OAC’s choice, because risk of interactions is higher with a 
bigger number of medicines.
VKA treatments have frequent pharmacological interactions that require strict 
monitoring in disease exacerbating phases, treatment modifications, or hospital 
admission.
DOACs interact with fewer drugs and offer a more stable level of anticoagula-
tion, being indicated in patients with polypharmacy. All of them are dependent on 
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P-glycoprotein (Pgp) transport for intestinal absorption. So concomitant use of 
inhibitors of this transport (amiodarone, ketoconazole, quinidine and verapamil) is 
expected to increase absorption and plasma concentration of DOACs, and inducers 
(rifampicin and carbamacepine) led to a decrease of its. Rivaroxaban and apixaban 
are partially metabolized by cytochrome P450 (CYP3A4), so agents considered inhibi-
tors (azolic antifungals, ritonavir, and macrolides) increase the effect, and inducers 
(rifampicin, phenytoin, carbamazepine, and phenobarbital) reduce it [8, 41].
2.5 Nutritional status
Attention to nutrition is fundamental to good clinical practice. Nutrition care 
improves patient outcomes and reduces healthcare costs. The feed MEGlobal Group 
on Nutrition in Healthcare proposed Nutrition Care Pathway recommending the 
steps: screen always, intervene promptly when needed, and supervene routinely [42].
The nutritional status may affect OAC activity; thus, protein deficit and hypo-
albuminemia in malnutrition patients raise plasma OAC concentration and, there-
fore, bleeding risk. Because of that, every elderly patient with NVAF may undergo 
nutritional status assessment before to initiate oral anticoagulation. As a screening 
tool, Mini Nutritional Assessment Short Form (MNA-SF) is the one recommended 
to identify malnutrition patients and the ones in risk for it [43].
2.6 Cognitive impairment
Dementia is not an anticoagulation contraindication by itself. Factors as sever-
ity, life expectancy, and adherence to therapy must be taken into account before 
indicating antithrombotic treatment [28].
Elderly patients with mild to moderate cognitive impairment (“Global Deterioration 
Scale” or GDS <5) have not increased bleeding risk and may receive OAC [2].
Labile INR in patients with VKA is related with progression of cognitive impair-
ment; thus, we should consider to change DOACs in patients with moderate impair 
of cognitive function [8].
We do not know the bleeding risk or the benefit of anticoagulation therapy in 
patients with NVAF and severe cognitive impairment (GDS 6–7), but this phase of 
dementia is related with greater mortality and poor quality of life [33]. Therefore, 
not initiating OAC is an option if we reach an agreement with family/caregiver.
Cognitive impairment determines poor therapy adherence, so OAC should be 
initiated in patients with a responsible caregiver [2].
2.7 Mobility and disability
To evaluate the instrumental activities of daily life is useful to assess the inde-
pendence to manage the medication, and to evaluate basic activities of daily life 
determines the access to INR control. These are two essential tools that may help to 
choose DOACs because they can improve adherence and security [2].
Although there is no evidence about OAC therapy risk/benefit ratio in patients 
with severe/total functional dependence, this situation is related with increase 
short- and long-term mortality and poor quality of life [30]; thus, it is fair to not 
indicate anticoagulation in these patients.
2.8 Life expectancy
The total life expectancy and free of disability may modify anticoagulation 
attitude in the elderly with NVAF. Currently, life expectancy varies a lot around the 
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world from the higher one of 84.1 years in Japan to the lowest one of 52.2 years in 
Sierra Leone. Because of that, different tools have been designed and validated to 
assess life expectancy in order to take the right decision, not only based on age but 
also considering function, frailty, and comorbidity, among other factors. Some of 
the most used ones are Schonberg index and Lee index, both of them available in 
http://ePrognosis.ucsf.edu, and Studentski tables of life expectancy according to 
gait speed published in 2011 [44].
The time that an intervention takes until it shows efficacy (lag time to benefit) 
may be taken into account as well. Managing anticoagulation therapy, this time to 
benefit is really short, so life expectancy over 6 months is enough to justify anti-
thrombotic drug use.
3. Dosage and profile of anticoagulant agent
Different meta-analyses [19, 20, 45, 46] have evaluated clinical randomized 
trials in patients over 75 years and have shown that DOACs are as effective in ictus 
prevention as warfarin; however, there are differences between type of OAC and 
dosage in the case of ictus/thromboembolism rate, major bleeding, and intracranial 
bleeding [47, 48]. Apixaban and edoxaban demonstrated less incidence of major 
bleeding in comparison with VKA; nevertheless, rivaroxaban and dabigatran 
110 mg have similar risk. Apixaban, edoxaban, and dabigatran were associated with 
lower rates of intracranial bleeding compared to VKA [46].
Regarding gastrointestinal bleeding, in patients over 75 years, dabigatran and 
edoxaban 60 mg have demonstrated increased gastrointestinal bleeding risk in 
comparison with VKA, and there is no enough evidence in regard to apixaban and 
rivaroxaban [14, 45].
A recent review establishes that in patients older than 75 years, apixaban 5 mg 
twice a day is a first choice and rivaroxaban 20 mg once daily, edoxaban 60 mg 
once daily, and dabigatran 110 mg twice a day are second choices [49]. Given the 
increasing complexity of drug prescription in the elderly, in 2008 “Fit fOR The 
Aged (FORTA) classification” was born with intent to guide clinicians to optimize 
it. Recently, a systematic review of scientific evidence plus the application of Delphi 
method and FORTA classification has been published assessing oral anticoagulation 
in elderly patients with AF taking into account efficacy, security, and tolerability. 
Among DOACs, only apixaban was included in category A (very beneficial) because 
it shows superiority in every endpoint, including major and intracranial bleeding, 
ictus prevention, and mortality [50]. Furthermore, real-life anticoagulation [51–53] 
use trials have been published recently showing similar results to pivotal trials.
4. Special considerations for dosing in the elderly
There are no randomized clinical trials evaluating anticoagulation effective-
ness and safety of the DOACs versus VKA in the clinical situations outlined below. 
The following recommendations are based on pivotal analyses of each of the new 
anticoagulants.
4.1 Elderly patient with renal failure
Chronic renal failure is a risk factor for both stroke and systemic embolism 
and in patients with atrial fibrillation (AF) [54]. Some studies using VKA have 
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demonstrated the overall benefit of anticoagulation in patients with moderate to 
severe renal insufficiency (creatinine clearance 15–49 ml/min) despite the increased 
risk of bleeding [55].
In patients with mild to moderate renal failure, direct anticoagulants have been 
shown to decrease the incidence of systemic thromboembolism and major bleeding 
compared to VKA [56].
Regarding safety in patients with moderate renal insufficiency (CrCl 30–49 ml/
min), apixaban has been shown to significantly reduce the risk of bleeding against 
VKA. No significant differences were found between dabigatran and rivaroxaban 
versus VKA [57]. Severe renal failure (CrCl <30 ml/min) was an exclusion criterion 
in the pivotal clinical trials of DOACs.
Analyzing pharmacokinetic properties, it is important to point out that 80% of 
dabigatran is eliminated by the kidneys, while in the case of rivaroxaban, apixaban, 
and edoxaban, the renal clearance is 35, 25, and 50, respectively. Based on this, 
dabigatran is contraindicated in patients with CrCl<30 ml/min and all “anti-factor 
X” when the CrCl is less than 15 ml/min [15].
In patients with severe renal failure (CrCl <15 ml/min), including dialysis 
patients, clinical guidelines suggest not to anticoagulate [15].
4.2 Elderly patient with liver failure
Metabolism through cytochrome P450 (CYP3A4) is null or insignificant in 
dabigatran and edoxaban, about 25% in apixaban and 30% in rivaroxaban.
In mild hepatic insufficiency with no alteration of coagulation, the use of 
DOACs is safe, although it is recommended to avoid concomitant use with other 
drugs that are metabolized by CYP or glycoprotein P [58]. Moderate to severe 
hepatic failure (Child-Pugh B or C) is a contraindication for anticoagulation with 
both VKA and DOACs.
4.3 Elderly patient with malnutrition or dysphagia
Unlike VKA, DOACs do not interact with elements of the diet. Data available 
for elderly people with low weight and corporal mass index are poor. Current 
recommendations subscribe not to modify the doses of rivaroxaban or dabigatran 
in patients with low weight. In patients with <60 kg, the dose of edoxaban should 
be set (30 mg/24 h) and is one of the two criteria necessary to recommend the dose 
reduction of apixaban (2.5 mg/12 h) [48].
The DOAC binding-protein coefficient is variable: 35% dabigatran, 50% 
edoxaban, 90% apixaban, and > 90% rivaroxaban [58]. There are no specific 
recommendations in this regard, and the published data do not indicate to modify 
the doses [15].
4.4 Elderly patient with a history of bleeding
In elderly patients with an episode of major bleeding, whether intracranial or 
digestive, in treatment with anticoagulants, it is recommended to individualize the 
decision of restarting anticoagulation, based on several conditions such as age, con-
trol of blood pressure, the origin of bleeding, suitable anticoagulation at the time 
of the bleeding, the need for antiplatelet therapy, the risk of ischemic stroke, and, 
in the case of intracranial origin, the location and severity of it. Anticoagulation 
should be initiated after treatment of the cause, with anticoagulants with a low risk 
of bleeding, waiting 4–8 weeks if the origin was intracranial [49].
Epidemiology and Treatment of Atrial Fibrillation
8
4.5 Elderly patient with cancer or terminal organ disease
There is no available evidence to establish recommendations on anticoagulant 
therapy in elderly patients with atrial fibrillation and cancer or terminal organ 
disease. In cancer patients with atrial fibrillation, the low efficacy and safety of 
VKA have been documented given the interactions with cancer treatment [55]. 
In this scenario, DOACs could provide great advantages due to their predictable 
action at fixed doses. Possible limitations would come from the hemorrhagic risk, 
especially in gastrointestinal and central nervous system tumors, and the potential 
interactions with antineoplastic treatment, especially if metabolized via CYP or 
glycoprotein P. In the case of terminal organ disease, the prescription of drugs that 
prolong life or prevent disability should be avoided or interrupted, especially if the 
time necessary to obtain the benefit exceeds life expectancy. With regard to anti-
coagulants, it is recommended to suspend whenever the life expectancy is less than 
6 months and is not a case of high thromboembolic risk [2, 59, 60].
4.6 Elderly patient during the perioperative period and surgery
DOACs, unlike VKA, can be maintained perioperatively, without the need for 
bridging therapy with heparin, given that their half-life is short, and the antico-
agulant effect decreases rapidly after stopping the drug. Taking into account renal 
function and the risk of bleeding from surgery, a safety time period prior to the 
intervention can be established without the need for biological control [61].
In invasive procedures with low or moderate risk of bleeding, the anti-factor Xa 
must be suspended 24 hours before the intervention and 36 hours, in the event of 
severe renal insufficiency (CrCl <30 ml/min). In the case of dabigatran, the with-
drawal should be 24–48 hours before, depending on the glomerular filtration rate. 
In high-risk bleeding procedures, anti-factor Xa must be discontinued 48 hours 
before the intervention and dabigatran 48–96 hours according to the glomerular 
filtration rate.
If urgent intervention is required, the procedure should be delayed at least the 
half-life of the drug (approximately 12 hours average) provided there is an end of 
effect parallel to the half-life (dabigatran, apixaban, and edoxaban) and consid-
ering the degree of renal elimination (25% apixaban, 50% edoxaban, and 80% 
dabigatran).
If this is not possible, there is an increased risk of bleeding that must be assessed 
against the urgency of the intervention. Prothrombin complex concentrates or 
recombinant factor VIIa should be used only in the event of significant hemorrhage, 
and not for prophylactic reversal [62]. In 2015, the European Medicine Agency 
approved the use of idarucizumab, a humanized monoclonal antibody, to reverse 
the effects of dabigatran in life-threatening bleeding episodes. Although not yet 
commercialized in Europe [63], the use of andexanet alfa has been tested for the 
reversal of the effects of the factor Xa inhibitors with favorable and promising 
results in elderly patients, still awaiting approval [64].
The resumption of treatment will depend on the postoperative hemorrhagic 
risk. In the case of major or urological abdominal surgery, we should wait for the 
absence of active hemorrhage visualized by the drainages. In procedures with good 
hemostasis, it can be restarted 6 hours after the intervention, but normally the 
indications are to restart anticoagulation 24 hours after the intervention; unless 
there is a high risk of bleeding, then it is suitable to wait 48/72 hours [65].
In dental extractions and other dental procedures, there is currently no knowl-
edge enough to establish recommendations with a high level of evidence. In the 
bibliography, being a low-risk procedure, it recommends limiting the extractions 
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to a maximum of two or three pieces and not stopping the anticoagulant treatment. 
It is recommended to perform the intervention about 12 hours after the last dose 
and not to take the next dose of DOAC until a good hemostasis is achieved, around 
6 hours later [66].
4.7 Nonagenarian and centennial patients
There are no data available on the efficacy and safety of DOACs in nonagenar-
ian and centennial patients [67]. As age increases, the risk of atrial fibrillation 
and embolism increases but also of bleeding [68]. Apixaban is the DOAC that has 
less renal elimination, and, compared to the VKA, apixaban and edoxaban at low 
doses (30 mg) are those that had lower rates of major hemorrhages in this age 
group, although the latter was less effective in the prevention of ischemic stroke. A 
subanalysis of the ARISTOTLE study concludes that patients with atrial fibrillation 
and a single associated factor (advanced age, low body weight, or renal dysfunc-
tion) have an increased risk of stroke or systemic embolism and major bleeding but 
show consistent benefits with the dose of 5 mg twice daily of apixaban vs. warfarin 
compared to patients without these characteristics. The dose of apixaban 5 mg twice 
daily is safe, effective, and appropriate for patients with only one dose-reduction 
criterion [69]. There is a study that indicates that there is an increased risk of 
ischemic stroke or systemic embolic event, in patients with a dose of apixaban  
2.5 versus warfarin [70].
4.8 Elderly patient with poor therapeutic compliance or social isolation
The lack of adherence to chronic treatment with oral anticoagulants increases 
the risk of thromboembolic and hemorrhagic complications [71]. Multiple reasons 
have been described associated with the lack of adherence to anticoagulant treat-
ment in the elderly, such as neuropsychiatric pathology, social situation, or lack 
of understanding of the disease [72]. DOACs present the advantages of the fixed 
dosage and do not need monitoring, which could improve the adherence and 
persistence of the treatment [71, 73, 74].
However, the transition from VKA to DOAC has not always been shown to 
ensure therapeutic compliance, which is even more important since this pharma-
cological group has a shorter half-life than VKA [22]. Therefore, an analysis of the 
reasons for nonadherence should always be performed before taking the anticoagu-
lation decision and choosing the type of anticoagulant [1–31, 33–39, 43–69, 75–77] 
as well as, if indicated, carrying out strategies to ensure compliance with long-term 
treatment, regardless of the type of anticoagulant [78].
It is known that therapeutic regimens of a single dose per day can improve 
adherence [79], although this aspect is questioned given the variability of drug 
concentration and the risk of events when a dose is forgotten [80].
5.  Comprehensive geriatric assessment before making a decision  
about OAC
As a result of what was previously exposed, it has been proposed to carry out 
a complete comprehensive geriatric assessment before to initiate anticoagulation 
treatment in people over 75 years with NVAF. The first step would be to assess a 
Barthel Index and Reisberg’s GDS scale as represented in Figure 2 [75]. Apart from the 
presence of Barthel Index ≥85 or GDS scale ≤5, it is also recommended to assess the 
short physical performance battery (SPPB) to identify frailty [35]. If frailty condition 
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was detected, Barthel Index is between 25 and 80, or if GDS scale is 6, it is necessary 
to include a comprehensive geriatric assessment with a Mini Nutritional Assessment 
Short Form (MNA-SF®) [43] for nutritional status, CIRS-G scale [76] to evaluate 
comorbidity], and STOPP/START criteria [77] to assess falling risk and polypharmacy 
and to identify potentially inappropriate medicines. Personalized anticoagulation use 
is the most important approach (Table 1).
6. Summary box
• The selection of the anticoagulant drug and its dose should be carried out 
individually and carefully, taking into account clinical, geriatric criteria, and 
the preferences of the patient.
• It seems reasonable that patients who do not receive such treatment should be 
limited to those with an obvious contraindication and those who are consid-
ered in short value because they are in the last days of their lives with very high 
competitive risks.
• In patients >75 years old, DOACs as a class were superior to warfarin with 
respect to both efficacy and safety, showing similar efficacy in the prevention 
of stroke and systemic embolization between them but with lowest risk of 
major bleeding for apixaban and lower rates of intracranial hemorrhage for 








Comprehensive geriatric assessment and possible approaches before OAC.
Figure 2. 
Algorithm deciding oral anticoagulation in older patients. Modified from Petidier et al. [75].
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